United States Biotechnology & Medical Research

Quince Therapeutics Inc (QNCX)

Track

The most recent insider trading activity at Quince Therapeutics Inc. occurred on December 26, 2025, when officer Luca Benatti executed a sale of 50,000 shares. Prior to this, insider activity consisted of various purchase transactions by executives throughout 2024 and 2023. No insider trading has been reported within the last three months.
Ticker: QNCX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Quince Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 26 Dec 2025
Value US$4,372,320.02 | Price 112.30 | Shares 55,504
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-29 2025-12-26 PrS Proposed sale
3.3
LUCA BENATTI

OFFICER

Officer
55,504
112.30
US$4,372,320 		55,504 112.30 US$4,372,320
2025-12-29 2025-12-26 S Sale
3.3
Benatti Luca
Non-Executive Director
68,542 -38.6%
90.13
US$3,914,905 		68,542 -38.6% 90.13 US$3,914,905
2024-09-03 2024-08-30 B Purchase
3.3
Thye Dirk

CEO AND CHIEF MEDICAL OFFICER

Executive Director
3,321 +9.2%
416.13
US$811,665 		3,321 +9.2% 416.13 US$811,665
2024-09-03 2024-08-29 B Purchase
3.3
Thye Dirk

CEO AND CHIEF MEDICAL OFFICER

Executive Director
77,500 +11.2%
0.69
US$53,475 		77,500 +11.2% 0.69 US$53,475
2024-08-21 2024-08-21 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
23,565 +8.6%
0.63
US$14,846 		23,565 +8.6% 0.63 US$14,846
2024-08-21 2024-08-21 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
5,000 +1.9%
0.62
US$3,100 		5,000 +1.9% 0.62 US$3,100
2024-08-21 2024-08-21 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
2,280 +0.9%
0.61
US$1,391 		2,280 +0.9% 0.61 US$1,391
2024-08-22 2024-08-20 B Purchase
3.3
Ryan Charles S.

PRESIDENT

Officer
48,387 +65.3%
0.65
US$31,452 		48,387 +65.3% 0.65 US$31,452
2024-08-21 2024-08-20 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
3,424 +1.3%
0.60
US$2,054 		3,424 +1.3% 0.60 US$2,054
2024-08-21 2024-08-20 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
2,500 +1.0%
0.61
US$1,525 		2,500 +1.0% 0.61 US$1,525
2024-08-21 2024-08-19 B Purchase
3.2
Hannah Brendan

CHIEF BUSINESS OFFICER AND COO

Officer
2,155 +0.8%
0.58
US$1,250 		2,155 +0.8% 0.58 US$1,250
2023-12-14 2023-12-14 B Purchase
3.7
Lamond David
Non-Executive Director
22,627 +1.0%
1.04
US$23,532 		22,627 +1.0% 1.04 US$23,532
2023-12-14 2023-12-13 B Purchase
3.7
Lamond David
Non-Executive Director
22,627 +1.0%
1.00
US$22,627 		22,627 +1.0% 1.00 US$22,627
2023-12-14 2023-12-12 B Purchase
3.7
Lamond David
Non-Executive Director
22,327 +1.0%
1.02
US$22,774 		22,327 +1.0% 1.02 US$22,774
2023-12-14 2023-12-12 B Purchase
3.7
Lamond David
Non-Executive Director
300 +0.0%
1.00
US$300 		300 +0.0% 1.00 US$300
2023-12-07 2023-12-07 B Purchase
3.7
Lamond David
Non-Executive Director
19,123 +0.8%
1.01
US$19,314 		19,123 +0.8% 1.01 US$19,314
2023-12-07 2023-12-06 B Purchase
3.7
Lamond David
Non-Executive Director
19,123 +0.9%
1.02
US$19,505 		19,123 +0.9% 1.02 US$19,505
2023-12-07 2023-12-05 B Purchase
3.7
Lamond David
Non-Executive Director
19,123 +0.9%
1.01
US$19,314 		19,123 +0.9% 1.01 US$19,314
2023-12-01 2023-12-01 B Purchase
3.7
Lamond David
Non-Executive Director
14,378 +0.7%
0.94
US$13,515 		14,378 +0.7% 0.94 US$13,515
2023-12-01 2023-11-30 B Purchase
3.7
Lamond David
Non-Executive Director
14,378 +0.7%
0.90
US$12,940 		14,378 +0.7% 0.90 US$12,940
2023-12-01 2023-11-29 B Purchase
3.7
Lamond David
Non-Executive Director
14,378 +0.7%
0.98
US$14,090 		14,378 +0.7% 0.98 US$14,090
2023-08-31 2023-08-31 B Purchase
3.7
Lamond David
Non-Executive Director
41,026 +1.9%
1.32
US$54,154 		41,026 +1.9% 1.32 US$54,154
2023-08-31 2023-08-30 B Purchase
3.7
Lamond David
Non-Executive Director
41,026 +2.0%
1.31
US$53,744 		41,026 +2.0% 1.31 US$53,744
2023-08-17 2023-08-17 B Purchase
3.7
Lamond David
Non-Executive Director
24,766 +1.2%
1.29
US$31,948 		24,766 +1.2% 1.29 US$31,948
2023-08-17 2023-08-16 B Purchase
3.7
Lamond David
Non-Executive Director
117,348 +6.0%
1.29
US$151,379 		117,348 +6.0% 1.29 US$151,379
2023-08-17 2023-08-15 B Purchase
3.7
Lamond David
Non-Executive Director
107,886 +5.8%
1.32
US$142,410 		107,886 +5.8% 1.32 US$142,410
2023-08-11 2023-08-10 B Purchase
3.3
Thye Dirk

Chief Executive Officer

Executive Director
88,000 +24.4%
1.26
US$110,880 		88,000 +24.4% 1.26 US$110,880
2023-08-09 2023-08-08 B Purchase
3.3
Thye Dirk

Chief Executive Officer

Executive Director
80,000 +28.5%
1.24
US$99,200 		80,000 +28.5% 1.24 US$99,200
2023-08-09 2023-08-08 B Purchase
3.2
Hannah Brendan

Chief Business Officer

Officer
71,762 +55.3%
1.22
US$87,550 		71,762 +55.3% 1.22 US$87,550
2023-08-09 2023-08-08 B Purchase
1.3
McLoughlin Margaret
Non-Executive Director
8,000 +inf%
1.23
US$9,840 		8,000 +inf% 1.23 US$9,840
2023-03-06 2023-03-06 PlS Planned sale
Monohon Ted

Chief Accounting Officer & VP

Officer
1,871 -6.4%
0.98
US$1,834 		1,871 -6.4% 0.98 US$1,834
2022-06-08 2022-06-06 S Sale
3.3
McDowell Caryn Gordon

Chief Legal & Adm. Officer

Officer
10,800 -8.1%
2.86
US$30,923 		10,800 -8.1% 2.86 US$30,923
2021-11-12 2021-11-12 B Purchase
0.5
Dominy Stephen S.

Chief Scientific Officer

Executive Director
763 +0.1%
14.40
US$10,987 		763 +0.1% 14.40 US$10,987
2021-10-12 2021-10-08 PlS Planned sale
1.3
McLoughlin Margaret
Non-Executive Director
1,000 -100.0%
88.93
US$88,930 		1,000 -100.0% 88.93 US$88,930
2021-10-07 2021-10-05 PlS Planned sale
0.8
LOWE CHRISTOPHER P.

COO & Chief Financial Officer

Officer
4,963 -7.6%
98.50
US$488,856 		4,963 -7.6% 98.50 US$488,856
2021-07-07 2021-07-07 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
523 -100.0%
56.99
US$29,806 		523 -100.0% 56.99 US$29,806
2021-07-07 2021-07-07 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
6,942 -93.0%
56.27
US$390,626 		6,942 -93.0% 56.27 US$390,626
2021-07-07 2021-07-07 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
4,353 -36.8%
55.38
US$241,069 		4,353 -36.8% 55.38 US$241,069
2021-07-07 2021-07-07 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
1,648 -12.2%
54.37
US$89,602 		1,648 -12.2% 54.37 US$89,602
2021-07-07 2021-07-07 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
3,934 -22.6%
53.24
US$209,446 		3,934 -22.6% 53.24 US$209,446
2021-07-07 2021-07-06 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
288 -100.0%
55.01
US$15,843 		288 -100.0% 55.01 US$15,843
2021-07-07 2021-07-06 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
8,260 -96.6%
53.91
US$445,297 		8,260 -96.6% 53.91 US$445,297
2021-07-07 2021-07-06 PlS Planned sale
Detke Michael J.

Chief Medical Officer

Officer
32,313 -79.1%
53.43
US$1,726,484 		32,313 -79.1% 53.43 US$1,726,484
2021-05-12 2021-05-10 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
183 -0.0%
36.73
US$6,722 		183 -0.0% 36.73 US$6,722
2021-05-12 2021-05-10 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
6,315 -0.6%
35.81
US$226,140 		6,315 -0.6% 35.81 US$226,140
2021-05-12 2021-05-10 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
9,918 -1.0%
34.89
US$346,039 		9,918 -1.0% 34.89 US$346,039
2021-05-12 2021-05-10 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
13,584 -1.3%
33.75
US$458,460 		13,584 -1.3% 33.75 US$458,460
2021-03-24 2021-03-24 B Purchase
3.7
Lamond David
Non-Executive Director
50,000 +2.8%
33.77
US$1,688,500 		50,000 +2.8% 33.77 US$1,688,500
2021-03-23 2021-03-22 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
400 -0.0%
36.60
US$14,640 		400 -0.0% 36.60 US$14,640
2021-03-23 2021-03-22 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
300 -0.0%
36.58
US$10,974 		300 -0.0% 36.58 US$10,974
2021-03-23 2021-03-22 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
18,089 -1.8%
35.85
US$648,491 		18,089 -1.8% 35.85 US$648,491
2021-03-23 2021-03-22 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
11,211 -1.1%
35.10
US$393,506 		11,211 -1.1% 35.10 US$393,506
2021-03-05 2021-03-04 B Purchase
3.7
Lamond David
Non-Executive Director
4,100 +0.2%
36.86
US$151,126 		4,100 +0.2% 36.86 US$151,126
2021-03-05 2021-03-04 B Purchase
3.7
Lamond David
Non-Executive Director
15,969 +0.9%
36.34
US$580,313 		15,969 +0.9% 36.34 US$580,313
2021-03-05 2021-03-04 B Purchase
3.7
Lamond David
Non-Executive Director
13,310 +0.8%
35.00
US$465,850 		13,310 +0.8% 35.00 US$465,850
2021-03-05 2021-03-04 B Purchase
3.7
Lamond David
Non-Executive Director
16,621 +1.0%
34.28
US$569,768 		16,621 +1.0% 34.28 US$569,768
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
600 -0.1%
45.73
US$27,438 		600 -0.1% 45.73 US$27,438
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
8,032 -0.8%
45.00
US$361,440 		8,032 -0.8% 45.00 US$361,440
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
1,900 -0.2%
44.22
US$84,018 		1,900 -0.2% 44.22 US$84,018
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
1,512 -0.1%
43.10
US$65,167 		1,512 -0.1% 43.10 US$65,167
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
3,100 -0.3%
41.91
US$129,921 		3,100 -0.3% 41.91 US$129,921
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
2,000 -0.2%
40.84
US$81,680 		2,000 -0.2% 40.84 US$81,680
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
856 -0.1%
39.82
US$34,086 		856 -0.1% 39.82 US$34,086
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
1,600 -0.2%
38.64
US$61,824 		1,600 -0.2% 38.64 US$61,824
2021-02-03 2021-02-03 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
400 -0.0%
37.39
US$14,956 		400 -0.0% 37.39 US$14,956
2021-02-03 2021-02-02 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
5,071 -0.5%
36.75
US$186,359 		5,071 -0.5% 36.75 US$186,359
2021-02-03 2021-02-02 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
14,929 -1.4%
36.02
US$537,743 		14,929 -1.4% 36.02 US$537,743
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
371 -0.0%
39.23
US$14,554 		371 -0.0% 39.23 US$14,554
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
100 -0.0%
38.28
US$3,828 		100 -0.0% 38.28 US$3,828
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
4,283 -0.4%
37.68
US$161,383 		4,283 -0.4% 37.68 US$161,383
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
7,460 -0.7%
36.56
US$272,738 		7,460 -0.7% 36.56 US$272,738
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
3,100 -0.3%
35.59
US$110,329 		3,100 -0.3% 35.59 US$110,329
2021-02-03 2021-02-01 PlS Planned sale
Lynch Casey

Chief Executive Officer

Executive Director
4,686 -0.4%
34.60
US$162,136 		4,686 -0.4% 34.60 US$162,136
2020-12-15 2020-12-14 PlS Planned sale
Holsinger Leslie

Executive Vice President

Officer
900 -20.5%
32.59
US$29,331 		900 -20.5% 32.59 US$29,331
2020-12-15 2020-12-14 PlS Planned sale
Holsinger Leslie

Executive Vice President

Officer
400 -8.3%
32.59
US$13,034 		400 -8.3% 32.59 US$13,034
Explore more

More insider trading research around Quince Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America